ASCO 2026: Latest updates in mRCC
Prof Sakai speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about the staging of therapies for metastatic gastric cancer.
He outlines which therapy is suited to first and second line therapy, with ongoing research for immunotherapy and targeted molecules work in combination for these patients.
In Japan we treat with chemotherapy for the patients with metastatic gastric cancer.
What drugs do you typically use as treatment?
S-1 or capecitabine plus platinum, cisplatin or oxaliplatin; for the patients with HER2 positive gastric cancer trastuzumab will be added to this combination. Second line ramucirumab plus paclitaxel is usually used.
What clinical trials and drugs are you currently interested in?
For me, now we focus on the immune checkpoint agents like nivolumab or pembrolizumab.
Are you researching MET?
Yes, but it’s difficult so successful data we don’t have.
What angiogenesis drugs are showing potential?
It’s a very good drug so we use ramuciriumab in clinical practice. Ramuciriumab is a very effective drug, I think.
ASCO 2026: Latest updates in mRCC
Best practice in precision medicine for prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
EAU 2024: Bladder cancer latest
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania